Drug intelligence / Profile preview

GW7845

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
Administration
Not Applicable (used Only In Research; Common Routes In Animal Studies: Oral, But Not Approved For Clinical Human Use)
01

Overview

**GW7845** is a synthetic small molecule acting as a potent and selective agonist of the nuclear receptor peroxisome proliferator-activated receptor gamma (**PPARγ**), which is involved in regulating metabolism, fatty acid β-oxidation, glucose utilization, cholesterol transport, and cellular differentiation[1][2][3][4][5][7][9]. GW7845 is also an L-tyrosine derivative, chemically described as (2S)-2-[(2-methoxycarbonylphenyl)amino]-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid[1][5]. Preclinical studies demonstrate that GW7845 can induce apoptosis, limit migration of cancer cells[3][8][10], and delay tumor formation (notably, in mouse mammary tumor models)[4][6]. GW7845 enhances expression of PPARγ-responsive genes, redirects macrophage cholesterol efflux to adipose tissue via SR-BI, and affects mitochondrial function, indicating a multifaceted role in cellular metabolism, signaling, and cancer biology[2][4][6][10]. GW7845 is used widely in research but not approved for therapeutic use in humans or animals[1].

Other names
GW7845GW-7845GW 7845
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on GW7845.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW7845.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call